Hot Article Directory San Andrés y Providencia: March 2011

Monday, March 28, 2011

Mono-Embolex

Mono-Embolex may be available in the countries listed below.

Ingredient matches for Mono-Embolex

Certoparin Sodium

Certoparin Sodium is reported as an ingredient of Mono-Embolex in the following countries:

Germany

International Drug Name Search

Friday, March 25, 2011

Anthramed

Anthramed may be available in the countries listed below.

Ingredient matches for Anthramed

Dithranol

Dithranol is reported as an ingredient of Anthramed in the following countries:

Indonesia

International Drug Name Search

Wednesday, March 23, 2011

Le-Gami

Le-Gami may be available in the countries listed below.

Ingredient matches for Le-Gami

Gemifloxacin

Gemifloxacin is reported as an ingredient of Le-Gami in the following countries:

India

International Drug Name Search

Tuesday, March 22, 2011

Valpro-ratiopharm Chrono

Valpro-ratiopharm Chrono may be available in the countries listed below.

Ingredient matches for Valpro-ratiopharm Chrono

Valproic Acid

Valproic Acid is reported as an ingredient of Valpro-ratiopharm Chrono in the following countries:

Poland

Valproic Acid semisodium (a derivative of Valproic Acid) is reported as an ingredient of Valpro-ratiopharm Chrono in the following countries:

Poland

International Drug Name Search

Monday, March 14, 2011

Ornex

Pronunciation: a-seet-a-MIN-oh-fen/soo-do-e-FED-rin
Generic Name: Acetaminophen/Pseudoephedrine
Brand Name: Examples include Alka-Seltzer Plus Cold/Sinus and Ornex

Ornex is used for:

Relieving symptoms such as pain and sinus congestion due to colds, upper respiratory infections, and allergies. It may also used for other conditions as determined by your doctor.

Ornex is an analgesic and decongestant combination. The analgesic works in the brain to help decrease pain. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages, which decreases stuffiness.

Do NOT use Ornex if:

you are allergic to any ingredient in Ornex

you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems

you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Ornex:

Some medical conditions may interact with Ornex. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of adrenal gland problems (eg, adrenal gland tumor), heart problems, high blood pressure, diabetes, blood vessel problems, stroke, glaucoma, an enlarged prostate or other prostate problems, seizures, an overactive thyroid, severe kidney problems, or liver problems (eg, hepatitis), or if you consume more than 3 alcohol-containing drinks per day

Some MEDICINES MAY INTERACT with Ornex. Tell your health care provider if you are taking any other medicines, especially any of the following:

Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, indomethacin, isoniazid, MAO inhibitors (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because side effects of Ornex may be increased

Anticoagulants (eg, warfarin), digoxin, or droxidopa because risk of bleeding, irregular heartbeat, or heart attack may be increased

Bromocriptine or hydantoins (eg, phenytoin) because side effects may be increased by Ornex

Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because effectiveness may be decreased by Ornex

This may not be a complete list of all interactions that may occur. Ask your health care provider if Ornex may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Ornex:

Use Ornex as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ornex may be taken with or without food.

If you miss a dose of Ornex, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Ornex.

Important safety information:

Ornex may cause dizziness, drowsiness, or blurred vision. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Ornex. Using Ornex alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

Do not take diet or appetite control medicines while you are taking Ornex without checking with you doctor.

Ornex contains acetaminophen and pseudoephedrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains acetaminophen or pseudoephedrine. If it does or if you are uncertain, contact your doctor or pharmacist.

Do NOT exceed the recommended dose or take Ornex for longer than prescribed without checking with your doctor.

If your symptoms do not improve within 5 to 7 days or if they become worse, check with your doctor.

Ornex may cause increased sensitivity to the sun. Avoid exposure to the sun, sunlamps, or tanning booths until you know how you react to Ornex. Use a sunscreen or protective clothing if you must be outside for a prolonged period.

Ornex may cause liver damage. If you consume 3 or more alcohol-containing drinks every day, ask your doctor if you should take Ornex or other pain relievers/fever reducers. Alcohol use combined with Ornex may increase your risk for liver damage.

Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Ornex.

Use Ornex with caution in the ELDERLY because they may be more sensitive to its effects.

Caution is advised when using Ornex in CHILDREN because they may be more sensitive to its effects.

PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Ornex, discuss with your doctor the benefits and risks of using Ornex during pregnancy. Ornex is excreted in breast milk. If you are or will be breast-feeding while you are using Ornex, check with your doctor or pharmacist to discuss the risks to your baby.

Possible side effects of Ornex:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; mood or mental changes; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; stomach pain; tremor; vision changes; yellowing of skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Ornex side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Ornex:

Store Ornex at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Ornex out of the reach of children and away from pets.

General information:

If you have any questions about Ornex, please talk with your doctor, pharmacist, or other health care provider.

Ornex is to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Ornex. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Ornex resources

Ornex Side Effects (in more detail)
Ornex Use in Pregnancy & Breastfeeding
Ornex Drug Interactions
Ornex Support Group
1 Review for Ornex - Add your own review/rating

Ornex Concise Consumer Information (Cerner Multum)

Sudafed Sinus Concise Consumer Information (Cerner Multum)

Compare Ornex with other medications

Fever
Sinus Symptoms

Sunday, March 13, 2011

Baladex

Baladex may be available in the countries listed below.

Ingredient matches for Baladex

Guaifenesin

Guaifenesin is reported as an ingredient of Baladex in the following countries:

Poland

Theophylline

Theophylline is reported as an ingredient of Baladex in the following countries:

Poland

International Drug Name Search

Vesanoïd

Vesanoïd may be available in the countries listed below.

Ingredient matches for Vesanoïd

Tretinoin

Tretinoin is reported as an ingredient of Vesanoïd in the following countries:

France

International Drug Name Search

Propafenone

In the US, Propafenone (propafenone systemic) is a member of the drug class group I antiarrhythmics and is used to treat Atrial Fibrillation, Atrial Flutter, Ventricular Tachycardia and Wolff-Parkinson-White Syndrome.

US matches:

Propafenone

Propafenone Sustained-Release Capsules

Propafenone Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C01BC03

CAS registry number (Chemical Abstracts Service)

0054063-53-5

Chemical Formula

C21-H27-N-O3

Molecular Weight

341

Therapeutic Category

Antiarrhythmic agent

Chemical Name

1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-

Foreign Names

Propafenonum (Latin)
Propafenon (German)
Propafénone (French)
Propafenona (Spanish)

Generic Names

Propafenone (OS: BAN, DCIT)
Propafénone (OS: DCF)
Propafenone Hydrochloride (OS: BANM, USAN, JAN)
Fenopraine hydrochloride (IS)
SA 79 (IS)
WZ 88462-3 (IS)
Propafenone Hydrochloride (PH: BP 2010, Ph. Eur. 6, USP 32)
Propafenoni hydrochloridum (PH: Ph. Eur. 6)

Brand Names

Polfenon
Polpharma, Poland

Propafenon Hexal
Hexal, Luxembourg

Propafenonã
Arena, Romania

Propafenon-Hexal
Hexal, Luxembourg

Rytmonorm
Abbott, Germany

Apo-Propafenone
Apotex, Canada

Arythmol
Abbott, United Kingdom; Abbott, Ireland

Cardiofenone
Polifarma, Italy

Cuxafenon
TAD, Germany

Fenorit
Scharper, Italy

Gen-Propafenone
Genpharm, Canada

Nistaken
Kendrick, Mexico

Normorytmin
Abbott, Argentina

Profenan
Slaviamed, Serbia

Profex
Taro, Israel

Prolekofen
Lek, Czech Republic; Sandoz, Slovakia

Pronon
Astellas, Japan

Propafen
Heimdall, Colombia; Zorka, Serbia

Propafenon AL
Aliud, Czech Republic; Aliud, Germany; Aliud, Hungary; Aliud, Romania

Propafenon Alkaloid
Alkaloid, Croatia (Hrvatska)

Propafenon Genericon
Genericon, Croatia (Hrvatska)

Propafenon HCl PCH
Pharmachemie, Netherlands

Propafenon Heumann
Heumann, Germany

Propafenon Hexal
Hexal, Germany

Propafenon Pharmavit
Walmark, Hungary

Propafenon Sandoz
Sandoz, Germany

Propafenon Siga
Sigapharm, Germany

Propafenon Stada
Stada, Germany

Propafenon
Alkaloid, Serbia; Alkaloid, Slovenia; Genericon, Austria

Propafenon-CT
CT Arzneimittel, Germany

Propafenone Alter
Alter, Italy

Propafenone DOC
DOC Generici, Italy

Propafenone Hydrochloride
Ethex, United States; KV Pharmaceutical, United States; Mutual, United States; Pliva, United States; Qualitest, United States; United Research, United States; URL, United States; Vintage, United States; Watson, United States

Propafenone Pensa
Pensa, Italy

Propafenone ratiopharm
Ratiopharm, Italy

Propafenone Sandoz
Sandoz, Italy

Propafenon-ratiopharm
Ratiopharm, Germany

Propanorm
Pro.Med.CS, Bosnia & Herzegowina; Pro.Med.CS, Czech Republic; Pro.Med.CS, Estonia; Pro.Med.CS, Georgia; Pro.Med.CS, Lithuania; Pro.Med.CS, Russian Federation; Pro.Med.CS, Slovakia

Ritmocor
Drugtech-Recalcine, Chile

Ritmonorm
Knoll, Brazil

Ropaful
Choseido Pharmaceutical, Japan

Rythmex
Teva, Israel

Rythmol
Abbott, Canada; Abbott, France; Abbott, South Africa; GlaxoSmithKline, United States

Rytmocard
Abbott, Philippines; Sopharma, Bulgaria

Rytmonorm
Abbott, Bosnia & Herzegowina; Abbott, Belgium; Abbott, Bulgaria; Abbott, Switzerland; Abbott, China; Abbott, Colombia; Abbott, Costa Rica; Abbott, Czech Republic; Abbott, Germany; Abbott, Denmark; Abbott, Estonia; Abbott, Spain; Abbott, Finland; Abbott, Georgia; Abbott, Guatemala; Abbott, Hong Kong; Abbott, Honduras; Abbott, Croatia (Hrvatska); Abbott, Hungary; Abbott, Indonesia; Abbott, Iceland; Abbott, Italy; Abbott, Lithuania; Abbott, Luxembourg; Abbott, Latvia; Abbott, Nicaragua; Abbott, Netherlands; Abbott, New Zealand; Abbott, Panama; Abbott, Peru; Abbott, Poland; Abbott, Portugal; Abbott, Romania; Abbott, Russian Federation; Abbott, Sweden; Abbott, Singapore; Abbott, Slovenia; Abbott, Slovakia; Abbott, El Salvador; Abbott, Thailand; Abbott, Turkey; Abbott, Taiwan; Abbott, Venezuela; Ebewe, Bulgaria; Ebewe, Romania; Knoll, United Arab Emirates; Knoll, Bahrain; Knoll, Egypt; Knoll, Iran; Knoll, Jordan; Knoll, Kuwait; Knoll, Lebanon; Knoll, Qatar; Knoll, Saudi Arabia

Rytmonorma
Abbott, Austria

Rytmo-Puren
Actavis, Germany

Sobiral
Ohara Yakuhin, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday, March 12, 2011

Leucodar

Leucodar may be available in the countries listed below.

Ingredient matches for Leucodar

Fluconazole

Fluconazole is reported as an ingredient of Leucodar in the following countries:

Bangladesh

International Drug Name Search

Friday, March 11, 2011

Tyvaso

Tyvaso is a brand name of treprostinil, approved by the FDA in the following formulation(s):

TYVASO (treprostinil sodium - solution; inhalation)

Manufacturer: UNITED THERAP

Approval date: July 30, 2009

Strength(s): EQ 0.6MG BASE/ML ^[RLD]

Has a generic version of Tyvaso been approved?

No. There is currently no therapeutically equivalent version of Tyvaso available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyvaso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method of treating pulmonary hypertension with benzidine prostaglandins
Patent 5,153,222
Issued: October 6, 1992
Inventor(s): Tadepalli; Anjaneyulu S. & Long; Walker A. & Crow; James W. & Klein; Kenneth B.
Assignee(s): Burroughs Wellcome Co.
The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --; R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, or R is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; and the dotted line represents an optional double bond; or of a physiologically acceptable salt or acid derivative thereof. Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
Patent expiration dates:
- October 16, 2014
  ✓
  Patent use: TREATMENT OF PULMONARY HYPERTENSION

Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
Patent 6,521,212
Issued: February 18, 2003
Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
Assignee(s): United Therapeutics Corporation
A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Patent expiration dates:
- November 13, 2018
  ✓
  Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

Method for delivering benzindene prostaglandins by inhalation
Patent 6,756,033
Issued: June 29, 2004
Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
Assignee(s): United Therapeutics Corporation
A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Patent expiration dates:
- November 13, 2018
  ✓
  Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

Process for stereoselective synthesis of prostacyclin derivatives
Patent 6,765,117
Issued: July 20, 2004
Inventor(s): Robert M.; Moriarty & Raju; Penmasta & Liang; Guo & Munagala S.; Rao & James P.; Staszewski
Assignee(s): United Therapeutic Corporation
An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. The invention also relates to novel intermediates prepared during the synthesis of the 9-deoxy-PGF1-type compounds.
Patent expiration dates:
- October 24, 2017
  ✓
  Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- July 30, 2012 - NEW DOSAGE FORM
- July 30, 2016 - ORPHAN DRUG EXCLUSIVITY

Monday, March 7, 2011

Cisplatine Mayne

Cisplatine Mayne may be available in the countries listed below.

Ingredient matches for Cisplatine Mayne

Cisplatin

Cisplatin is reported as an ingredient of Cisplatine Mayne in the following countries:

Luxembourg

International Drug Name Search

Sunday, March 6, 2011

Nongonococcal Urethritis Medications

Definition of Nongonococcal Urethritis: Urethritis not resulting from gonococcal infection. Venereally transmitted Chlamydia trachomatis is the most common cause.

Drugs associated with Nongonococcal Urethritis

The following drugs and medications are in some way related to, or used in the treatment of Nongonococcal Urethritis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.